Published on
February 24, 2024
- 14:51 GMT
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity ...
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed rilzabrutinib, an oral BTK inhibitor, significantly …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Media, Advertising & PR
...
